8 April 2024 ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer
4 April 2024 ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation